Profound systemic alteration of the immune phenotype and an immunoglobulin switch in Erdheim-Chester disease in 78 patients from a single center

Haematologica. 2022 Jun 1;107(6):1347-1357. doi: 10.3324/haematol.2021.279118.

Abstract

Erdheim-Chester disease (ECD) is a rare, systemic, non-Langerhans cell histiocytosis neoplasm, which is characterized by the infiltration of CD63+ CD1a- histiocytes in multiple tissues. The BRAFV600E mutation is frequently present in individuals with ECD and has been detected in hematopoietic stem cells and immune cells from the myeloid and systemic compartments. Immune cells and pro-inflammatory cytokines are present in lesions, suggesting that ECD involves immune cell recruitment. Although a systemic cytokine T-helper-1-oriented signature has been reported in ECD, the immune cell network orchestrating the immune response in ECD has yet to be described. To address this issue, the phenotypes of circulating leukocytes were investigated in a large, single-center cohort of 78 patients with ECD and compared with those of a group of 21 control individuals. Major perturbations in the abundance of systemic immune cells were detected in patients with ECD, with decreases in circulating plasmacytoid, myeloid 1, and myeloid 2 dendritic cells, mostly in BRAFV600E carriers, in comparison with individuals in the control group. Similarly, marked decreases in blood Thelper, cytotoxic, and B-lymphocyte numbers were observed in patients with ECD, relative to the control group. Measurement of circulating immunoglobulin concentrations revealed an immunoglobulin G switch, from IgG1 to IgG4 subclasses, which are more frequently associated with the BRAF mutation. First-line therapies, including pegylated interferon-a and vemurafenib, were able to correct most of these alterations. This study reveals a profound disturbance in the systemic immune phenotype in patients with ECD, providing important new information, helping to understand the physiopathological mechanisms involved in this rare disease and improving the therapeutic management of patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines / genetics
  • Erdheim-Chester Disease* / diagnosis
  • Erdheim-Chester Disease* / drug therapy
  • Erdheim-Chester Disease* / genetics
  • Humans
  • Immunoglobulin G
  • Phenotype
  • Proto-Oncogene Proteins B-raf / genetics
  • Vemurafenib / therapeutic use

Substances

  • Cytokines
  • Immunoglobulin G
  • Vemurafenib
  • Proto-Oncogene Proteins B-raf

Grants and funding

Funding: INSERM, Sorbonne Université, French National Agency (ANR-10-IAHU-05), and the Erdheim-Chester Disease Global Alliance.